Pfizer, Concerto HealthAI Partner on Precision Oncology
The collaboration will conduct novel synthetic control arm and prospective RWD outcomes study designs for both pre- and post-approval therapeutics with the goal of speeding up study completion for Pfizer‘s investigational therapies and commercialized therapeutics used to treat solid tumors and hematologic malignancies.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.